Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab

NCT03328026 is registered in ClinicalTrials.gov with BriaCell Therapeutics Corporation as lead sponsor.

NCT NCT03328026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03328026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Lead sponsor
BriaCell Therapeutics Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
March 16, 2018
Completion date
March 24, 2026
Enrollment
36 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer metastatic, breast neoplasm, metastatic breast cancer